Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early Medication Change (EMC) vs Treatment as Usual (TAU) in Major Depressive Disorder
2008-008280-96Phase 4Completed
- Sponsor
- Johannes Gutenberg University Mainz
- Start
- Jul 2009
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of escitalopram, venlafaxine and lithium in major depressive disorder (MDD) (2 arms), sponsored by Johannes Gutenberg University Mainz. Primary endpoint: Remission from major depressive disorder. Started Jul 2009; status: completed.
02
Drugs
escitalopramvenlafaxinelithium
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2008-008280-96.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-008280-96.